Company to Present at the Upcoming 2023 Annual Meeting of the American Association for Cancer Research (AACR)
- ImmunoPrecise’s Unique Proprietary Bispecific Antibodies Link Cells Expressing Tumor-Associated Antigen Tropomyosin Receptor Kinase B (TrkB) with CD3-Positive T Cells, Immune System Cells that Respond by Recognizing and Eliminating Cancer Cells.
- The Company’s Potential Therapeutic, which is Designed to Bring TrkB-Expressing Tumor Cells in Contact with Engaged and Activated T Cells, may Represent a Novel First-in-Class Therapeutic for Targeting TrkB-Associated Tumors in such Cancers as Non-Small Cell Lung, Breast, Colon, Head, Neck, and Pancreatic.
- Studies Show Most Tumors from These Cancers Express High Levels of TrkB1, and the Protein’s Presence is Associated with Poor Prognosis and Low Survival Rates.
- The Company has Filed a Provisional Patent Application to the United State Patent and Trademark Office.
VICTORIA, Canada I March 23, 2023 I Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, is pleased to announce that its wholly owned subsidiary, Talem Therapeutics, will present a scientific poster with their latest data on the development of bispecific T-cell engagers targeting TrkB at the annual AACR meeting in Orlando, Florida, which is held from April 14 to 19, 2023. With this advanced development to target TrkB-expressing tumor cells, IPA differentiates itself from other organizations developing immunotherapeutics to treat malignant solid tumors.
The (over)expression of TrkB and (over)activation of the TrkB-signaling pathway play a crucial role in various malignancies and are associated with poor disease outcomes. Currently applied pharmaceuticals target TrkB through interference with its tyrosine kinase activity, but they lack specificity and are therefore associated with many adverse effects. At the 2023 annual AACR meeting, IPA will present their novel therapeutic design, exhibiting high specificity to the tumor-associated protein TrkB, shown to be associated with cancer cell survival, proliferation, migration, and resistance to chemotherapy. The Company will share data demonstrating the evidence for the potential therapeutic’s ability to recruit and activate T cells to target TrkB-specific tumors, in what they believe may be a safer, more effective, and more targeted cancer therapy. The importance of the invention was appreciated in a provisional patent application filed by Talem Therapeutics to the United State Patent and Trademark Office.
Dr. Jennifer Bath, IPA’s CEO and President, stated: “For years, we have consistently demonstrated success in creating clinically relevant therapies for our clients and partners by utilizing our advanced drug discovery and analytical capabilities. We take pride in revealing the details of a pioneering bispecific therapy that aims to revolutionize the approach to targeting and treating various solid tumors. Our continuous goal is to create safer and more precise therapies, as we collaborate with our partners to develop the future generation of cancer treatment options.”
The Poster Presentation
“Bispecific T cell engagers targeting TrkB”
IPA will exhibit their poster number 29 in section 25 on Monday April 17th, from 9.00 am to 12.30 pm. The session category is ‘Immunology’, and the session is entitled ‘Therapeutic Antibodies 1’. An abstract of the poster is presented under number 1890.
- Meng, L.; Liu, B.; Ji, R.; Jiang, X.; Yan, X.; Xin, Y. Targeting the BDNF/TrkB Pathway for the Treatment of Tumors (Review). Oncol Lett 2018. https://doi.org/10.3892/ol.2018.9854.
About Immunoprecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”). The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. For further information, visit www.ipatherapeutics.com.
SOURCE: Immunoprecise Antibodies
Post Views: 211
Company to Present at the Upcoming 2023 Annual Meeting of the American Association for Cancer Research (AACR)
- ImmunoPrecise’s Unique Proprietary Bispecific Antibodies Link Cells Expressing Tumor-Associated Antigen Tropomyosin Receptor Kinase B (TrkB) with CD3-Positive T Cells, Immune System Cells that Respond by Recognizing and Eliminating Cancer Cells.
- The Company’s Potential Therapeutic, which is Designed to Bring TrkB-Expressing Tumor Cells in Contact with Engaged and Activated T Cells, may Represent a Novel First-in-Class Therapeutic for Targeting TrkB-Associated Tumors in such Cancers as Non-Small Cell Lung, Breast, Colon, Head, Neck, and Pancreatic.
- Studies Show Most Tumors from These Cancers Express High Levels of TrkB1, and the Protein’s Presence is Associated with Poor Prognosis and Low Survival Rates.
- The Company has Filed a Provisional Patent Application to the United State Patent and Trademark Office.
VICTORIA, Canada I March 23, 2023 I Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, is pleased to announce that its wholly owned subsidiary, Talem Therapeutics, will present a scientific poster with their latest data on the development of bispecific T-cell engagers targeting TrkB at the annual AACR meeting in Orlando, Florida, which is held from April 14 to 19, 2023. With this advanced development to target TrkB-expressing tumor cells, IPA differentiates itself from other organizations developing immunotherapeutics to treat malignant solid tumors.
The (over)expression of TrkB and (over)activation of the TrkB-signaling pathway play a crucial role in various malignancies and are associated with poor disease outcomes. Currently applied pharmaceuticals target TrkB through interference with its tyrosine kinase activity, but they lack specificity and are therefore associated with many adverse effects. At the 2023 annual AACR meeting, IPA will present their novel therapeutic design, exhibiting high specificity to the tumor-associated protein TrkB, shown to be associated with cancer cell survival, proliferation, migration, and resistance to chemotherapy. The Company will share data demonstrating the evidence for the potential therapeutic’s ability to recruit and activate T cells to target TrkB-specific tumors, in what they believe may be a safer, more effective, and more targeted cancer therapy. The importance of the invention was appreciated in a provisional patent application filed by Talem Therapeutics to the United State Patent and Trademark Office.
Dr. Jennifer Bath, IPA’s CEO and President, stated: “For years, we have consistently demonstrated success in creating clinically relevant therapies for our clients and partners by utilizing our advanced drug discovery and analytical capabilities. We take pride in revealing the details of a pioneering bispecific therapy that aims to revolutionize the approach to targeting and treating various solid tumors. Our continuous goal is to create safer and more precise therapies, as we collaborate with our partners to develop the future generation of cancer treatment options.”
The Poster Presentation
“Bispecific T cell engagers targeting TrkB”
IPA will exhibit their poster number 29 in section 25 on Monday April 17th, from 9.00 am to 12.30 pm. The session category is ‘Immunology’, and the session is entitled ‘Therapeutic Antibodies 1’. An abstract of the poster is presented under number 1890.
- Meng, L.; Liu, B.; Ji, R.; Jiang, X.; Yan, X.; Xin, Y. Targeting the BDNF/TrkB Pathway for the Treatment of Tumors (Review). Oncol Lett 2018. https://doi.org/10.3892/ol.2018.9854.
About Immunoprecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”). The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. For further information, visit www.ipatherapeutics.com.
SOURCE: Immunoprecise Antibodies
Post Views: 211
